Notably, there was a short follow-up time for the primary analysis, which prompted the investigators to repeat the analysis after an additional year of follow-up to assess PFS durability. At the 2.1-year follow-up point, 2-year PFS was 92% (95% CI, 89-94%) following N+AVD and 83% (95% CI, 39-86%) following BV+AVD.1
OS and EFS data were similarly positive. In the N+AVD group, 2-year OS and EFS was 99% and 90%, respectively, while in the BV-AVD group, OS and EFS was 98% and 81%, respectively. In an important development, nearly all AEs that occurred—apart from neutropenia and arthralgia—were more frequent with BV+AVD. Overall, the primary and secondary end points were successfully reached, showing significant improvements in response with N+AVD compared with BV+AVD.1
About the Trial
Trial Name: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
ClinicalTrials.gov ID: NCT03907488
Sponsor: National Cancer Institute (NCI)
Estimated Completion Date: April 1, 2025
Patients that received N+AVD had fewer deaths occur during treatment, a lower incidence of immune-related toxic effects, and fewer patients stopping treatment early, making up the superior safety profile it exhibited compared with BV+AVD. There were also a small number of patients that received end-of-treatment radiotherapy, which was a dramatic shift compared with the use of contemporary agents and suggests that radiotherapy has limited help to patients after treatment with N+AVD.1
Of note, BV+AVD was associated with a particularly “unacceptable” safety profile in older patients, with one-third of them discontinuing treatment early, in addition to high mortality rates. Based on these findings, the investigators recommended that the use of BV+AVD probably be avoided in older patients.1
“On the basis of the clinically meaningful improvement in progression-free survival and excellent side-effect profile of N+AVD, N+AVD should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” the study authors concluded.1
REFERENCES
1. Herrera AF, LeBlanc SM, Castellino H, et al. Nivolumab+AVD in advanced-stage classic Hodgkin’s lymphoma. N Engl J Med. 2024;391(15):1379-1389. doi:10.1056/NEJMoa2405888
2. ClinicalTrials.gov. Immunotherapy (nivolumab or brentuximab vedotin) plus combination chemotherapy in treating patients with newly diagnosed stage III-IV classic Hodgkin lymphoma. National Library of Medicine. Updated October 8, 2024. Accessed October 16, 2024.
3. McGovern G. FDA approves nivolumab for the treatment of adult patients with resectable NSCLC. Pharmacy Times. Updated October 4, 2024. Accessed October 16, 2024. https://www.pharmacytimes.com/view/fda-approves-nivolumab-for-the-treatment-of-adult-patients-with-resectable-nsclc